{"id":2208,"date":"2025-01-07T11:58:32","date_gmt":"2025-01-07T11:58:32","guid":{"rendered":"https:\/\/onltherapeutics.com\/test\/?page_id=2208"},"modified":"2025-10-28T11:40:05","modified_gmt":"2025-10-28T11:40:05","slug":"penny-fleck","status":"publish","type":"page","link":"https:\/\/onltherapeutics.com\/test\/penny-fleck\/","title":{"rendered":"Penny Fleck"},"content":{"rendered":"\n
<\/div>\n\n\n\n
\n
\n

Penny Fleck, MT, MBA<\/strong>
Chief Development Officer<\/h3>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"Penny<\/figure>\n<\/div>\n\n\n\n
\n

Penny is responsible for all development activities for the company\u2019s lead asset, xelafaslatide (formerly ONL1204). She brings over two decades of experience leading R&D organizations and portfolio clinical development strategies at major pharmaceutical companies and has a proven ability to advance assets through clinical development to regulatory approval and launch. As vice president and global head of specialty ophthalmology clinical development at Johnson & Johnson Innovative Medicine, she led the clinical development organization and was instrumental in building a portfolio of assets focused on both rare and common retinal conditions. Prior to joining Johnson & Johnson, Penny led the development and approval of multiple assets at Takeda Pharmaceutical across a number of disease areas including gastrointestinal, diabetes, and obesity. Penny holds a Bachelor of Science in medical technology from the University of Cincinnati and an MBA from Loyola University.\u00a0<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
Back to Our Team<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Penny Fleck, MT, MBAChief Development Officer Penny is responsible for all development activities for the company\u2019s lead asset, xelafaslatide (formerly ONL1204). She brings over two decades of experience leading R&D organizations and portfolio clinical development strategies at major pharmaceutical companies and has a proven ability to advance assets through clinical development to regulatory approval and […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"blank","meta":{"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-2208","page","type-page","status-publish","hentry"],"featured_image_urls_v2":{"full":"","thumbnail":"","medium":"","medium_large":"","large":"","1536x1536":"","2048x2048":"","gform-image-choice-sm":"","gform-image-choice-md":"","gform-image-choice-lg":""},"post_excerpt_stackable_v2":"

Penny Fleck, MT, MBAChief Development Officer Penny is responsible for all development activities for the company\u2019s lead asset, xelafaslatide (formerly ONL1204). She brings over two decades of experience leading R&D organizations and portfolio clinical development strategies at major pharmaceutical companies and has a proven ability to advance assets through clinical development to regulatory approval and launch. As vice president and global head of specialty ophthalmology clinical development at Johnson & Johnson Innovative Medicine, she led the clinical development organization and was instrumental in building a portfolio of assets focused on both rare and common retinal conditions. Prior to joining Johnson…<\/p>\n","category_list_v2":"","author_info_v2":{"name":"theo@myriadweb.com","url":"https:\/\/onltherapeutics.com\/test\/author\/theomyriadweb-com\/"},"comments_num_v2":"0 comments","_links":{"self":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/2208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/comments?post=2208"}],"version-history":[{"count":3,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/2208\/revisions"}],"predecessor-version":[{"id":2554,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/2208\/revisions\/2554"}],"wp:attachment":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/media?parent=2208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}